<DOC>
	<DOC>NCT00782574</DOC>
	<brief_summary>A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with advanced solid tumours. Approximately 50 (max 60) patients from 2 countries will be enrolled.</brief_summary>
	<brief_title>Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Life expectancy of at least 12 weeks Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent Patients with measurable or non measurable disease according to RECIST Less than 28 days from active therapy (ie any treatment used to treat the disease) or high dose radiotherapy Brain Metastases or spinal cord compression unless irradiated at least 4 weeks before entry and stable without steroid treatment for &gt;1 week Persistent CTCAE Grade 2 or greater toxicities (excluding alopecia) caused by prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid tumours</keyword>
	<keyword>Poly(ADP ribose) polymerases</keyword>
	<keyword>homologous deficiency</keyword>
	<keyword>BRCA1</keyword>
</DOC>